|
|
|
| Effects of Moxifloxacin Combined Seretide on Serum SAA TGF-β1 Copeptin, and sICAM-1 of AEC OPD |
| YU Qing, WANG Jingze |
| Chifeng Hospital, Inner Mongolia Chifeng 024000, China |
|
|
|
|
Abstract Objective: To study the clinical efficacy of moxifloxacin combined seretide inhalation in acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and its effects on serum amyloid A (SAA), transforming growth factor-β1 (TGF -β1), copeptin, soluble intercellular adhesion factor-1 (sICAM-1). Methods: A total of 102 AECOPD patients were enrolled of our hospital from December 2015 to December 2016. They were randomly divided into control group and experimental group (n = 51). The control group was treated with seretide combined Amoxicillin - clavulanic acid inhalation on the basis of routine treatment. The experimental group was treated with moxifloxacin combined seretide inhalation. To compare the changes of serum SAA, TGF-β1, copeptin and sICAM-1 in two groups, to observe the changes of serum CO2A (PaCO2) and oxygen partial pressure (PaO2), and to detect lung function: (FEV1), vital capacity (FVC) and FEV1 / FVC were used to assess the quality of life and dyspnea of patients with COPD: Medical Research Council Dyspnoea Scale( mMRC), COPD Assessment Test( CAT), and adverse events. Results: After treatment, the effective rate (92.16%) in the experimental group was significantly higher than that in the control group (P <0.05). FEV1, FCV, FEV1 / FCV were improved after treatment, the difference was statistically significant (P <0.05), and the experimental group improved more than the control group (P <0.05). Compared with the control group, the difference was statistically significant (P <0.05). The PaO2 of the two groups was significantly higher than that of the control group (P <0.05)., and the experimental group was significantly lower than the control group (P <0.05), the difference was statistically significant (P <0.05), and the difference was statistically significant (P <0.05). There was no significant difference between the two groups (P> 0.05). Conclusion: The clinical efficacy of moxifloxacin combined seretide inhalation on AECOPD patients can reduce serum SAA, TGF-β1, copeptin, sICAM-1 levels, improve arterial oxygen pressure, quality of life and lung function.
|
|
|
|
|
|
[1] 卫丽,白涛敏,穆志龙,等.早期小剂量糖皮质激素对儿童重症肺炎血清TNF-α、sICAM-1水平的影响[J].疑难病杂志,2016,15(7):729~732.
[2] 张细江,曹同瓦,赵锋.重症肺炎患者copeptin与病情严重性、预后及应激性高血糖的关系[J].中华急诊医学杂志,2016,25(3):338~342.
[3] 慢性阻塞性肺疾病急性加重诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2014年修订版)[J].国际呼吸杂志,2014,34(1):1~11.
[4] 张小娥,张彩莲.早期慢性阻塞性肺疾病研究进展[J].临床误诊误治,2017,30(6):112~116.
[5] 李珍,徐鸥.降钙素原在慢性阻塞性肺疾病急性加重期的应用及进展[J].临床肺科杂志,2015(4):728~732.
[6] 胡幼芳.莫西沙星的药理作用与临床应用[J].湖北科技学院学报,2015(8):7~8.
[7] 何攀文,李霞,叶胜兰,等.SAA、CRP、ESR联合检测在AECOPD病情监测中的价值分析[J].武汉大学学报(医学版),2017,38(2):280~282.
[8] 何绿苑,臧敏,应延风.COPD患者不同病期气道上皮细胞分泌TGF-β_1、PGE_2的水平变化[J].临床医学研究与实践,2016,1(5):5~6.
[9] 张俣,王筠,李晓萍,等.慢性阻塞性肺疾病患者和肽素、降钙素原水平变化及临床意义[J].世界最新医学信息文摘:连续型电子期刊,2016,16(77):80~81.
[10] 谢飞,王云,张吉才.和肽素与降钙素原检测在慢性阻塞性肺疾病急性加重期的临床意义[J].湖北医药学院学报,2014(2):121~123.
[11] 袁平,王文君,李东风,等.阻塞性睡眠呼吸暂停低通气综合征患者巨噬细胞移动抑制因子的表达及其与血管内皮细胞损伤的关系研究[J].中华结核和呼吸杂志,2016,39(11):871~875. |
|
|
|
2018, Vol. 24 
